Form 4: Royalty Pharma CFO Sells Shares Under 10b5-1 Plan

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.68 million under a pre-arranged 10b5-1 trading plan on November 24, 2025.

Summary

• Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc, reported the sale of 69,582 Class A Ordinary Shares.
• The transactions occurred on November 24, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 8, 2025.
• The shares were sold in multiple transactions at weighted average prices ranging from $37.9595 to $38.6699 per share, totaling approximately $2,684,279.98.
• Following these transactions, Mr. Coyne beneficially owns 1,480,368 Class A Ordinary Shares directly and indirectly through various entities and family accounts.
• Additionally, Mr. Coyne and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some subject to vesting and convertible to Class A shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports a routine insider stock sale conducted under a pre-arranged 10b5-1 plan, which is a common practice and does not inherently signal positive or negative company-specific news.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, indicating a scheduled transaction rather than a reaction to new, undisclosed negative information.
• Mr. Coyne retains a substantial beneficial ownership in Royalty Pharma plc, including direct, indirect, and exchangeable interests, demonstrating continued alignment with shareholder interests.

Negatives

• Insider selling, even if pre-planned, reduces the direct equity stake of a key executive in the company, which can sometimes be perceived negatively by the market.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

This Form 4 filing reports past transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

Industry Context

Form 4 filings are routine disclosures for executives of publicly traded companies, reporting changes in beneficial ownership. The use of a Rule 10b5-1 plan for stock sales is a common practice among corporate insiders to manage personal finances while adhering to insider trading regulations, by pre-scheduling transactions at a time when they are not in possession of material non-public information.

Related Party Transactions

• Indirect beneficial ownership of Class A Ordinary Shares is held through TPC RP 2021, LLC and TPC RP EPA1 LLC, as well as through a spouse's IRA and a spouse's direct holdings, all controlled by or related to the reporting person.

Stakeholder Impact

• Shareholders may note the reduction in direct executive ownership, but the pre-planned nature of the sales under a 10b5-1 plan typically mitigates concerns about the executive's confidence in the company's future.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The reported insider sales by Terrance P. Coyne, EVP & CFO, were conducted under a pre-arranged 10b5-1 trading plan, indicating a scheduled transaction rather than a reaction to new material information. While insider selling can sometimes be viewed negatively, the pre-planned nature suggests it is part of personal financial management and not necessarily a bearish signal for Royalty Pharma plc. Therefore, the filing itself does not provide a strong basis to alter an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Royalty Pharma, RPRX, insider trading, Form 4, stock sale, executive compensation, 10b5-1 plan, Terrance P. Coyne